Guanfacine
Small molecule targets ADRA2B
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Intuniv | — | 2015-09-17 | europa.eu ↗ |
| Label expansions (4) | US (FDA) | INTUNIV | — | 2011-02-25 – 2015-03-18 | fda.gov ↗ |
| Label expansion | US (FDA) | TENEX | — | 1993-05-11 | fda.gov ↗ |
| Approved | US (FDA) | TENEX | — | 1986-10-27 | fda.gov ↗ |
Trials 65 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04737512 | Feb 2021 → Oct 2024 | attention deficit-hyperactivity disorder | Yale University | Completed | No outcome recorded |
| Phase 16 trials | ||||||
| Phase 1 | NCT06642181 | Jul 2025 → Aug 2026 overdue | substance-related disorder | Rutgers, The State University of New Jersey | Recruiting | No outcome recorded |
| Phase 1 | NCT01467999 | Feb 2012 → Apr 2016 | cannabis dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 1 | NCT00901576 | May → Jul 2009 | — | Shire | Completed | No outcome recorded |
| Phase 1 | NCT00672984 | Apr → Aug 2008 | — | Shire | Completed | No outcome recorded |
| Phase 1 | NCT00223717 | Jan 2001 → Jan 2017 | hypertensive disorder | Vanderbilt University | Completed | No outcome recorded |
| Phase 1 | NCT00018603 | Nov 1999 → Oct 2002 | post-traumatic stress disorder | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03137082 | Jul 2017 → Mar 2021 | alcohol withdrawal | Stony Brook University | Completed | No outcome recorded |
| Phase 219 trials | ||||||
| Phase 2 | NCT06408246 | Mar 2026 → Oct 2028 expected | depressive disorder | Stanford University | Recruiting | No outcome recorded |
| Phase 2 | NCT07393334 | Dec 2025 → Mar 2026 overdue | — | Next Life Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT06629259 | Oct 2025 → Aug 2029 expected | alcohol-related disorders | Indiana University | Recruiting | No outcome recorded |
| Phase 2 | NCT05957848 | Jul 2023 → Dec 2025 overdue | cannabis dependence | Orygen | Recruiting | No outcome recorded |
| Phase 2 | NCT05273567 | Jun 2022 → Jul 2024 | cannabis dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 2 | NCT04742673 | May 2021 → Mar 2024 | delirium | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT04198116 | Nov 2020 → Apr 2025 | — | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT03764098 | Aug 2020 → Aug 2026 overdue | alcohol-related disorders | Yale University | Recruiting | No outcome recorded |
| Phase 2 | NCT03865940 | Nov 2019 → Oct 2023 | trigeminal neuralgia | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT03980184 | Nov 2019 → Nov 2022 | substance-related disorder | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT02164422 | Jun 2014 → Mar 2020 | alcohol-related disorders | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT02051309 | Mar 2014 → Nov 2020 | — | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT02524899 | Jan 2014 → Jan 2017 | schizotypal personality disorder | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2 | NCT01904526 | Jul 2013 → Dec 2016 | — | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT00955253 | Apr 2010 → Mar 2014 | mirror agnosia, stroke disorder | Imperial College London | Completed | No outcome recorded |
| Phase 2 | NCT00773357 | Oct 2008 → Jul 2021 | — | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT00613015 | May 2008 → Jul 2012 | cocaine dependence | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 2 | NCT00150592 | May → Oct 2005 | attention deficit-hyperactivity disorder | Shire | Completed | No outcome recorded |
| Phase 2 | NCT00151996 | Aug → Dec 2004 | attention deficit-hyperactivity disorder | Shire | Completed | No outcome recorded |
| Phase 312 trials | ||||||
| Phase 3 | NCT04578886 | Nov 2020 → Feb 2023 | delirium | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 3 | NCT01500694 | Mar 2012 → Sep 2015 | attention deficit-hyperactivity disorder | Shire | Completed | No outcome recorded |
| Phase 3 | NCT01081132 | Sep 2011 → May 2013 | attention deficit-hyperactivity disorder | Shire | Completed | No outcome recorded |
| Phase 3 | NCT03662763 | Sep 2011 → Aug 2013 | attention deficit-hyperactivity disorder | Maastricht University Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01244490 | Jan 2011 → May 2013 | attention deficit-hyperactivity disorder | Shire | Completed | No outcome recorded |
| Phase 3 | NCT01081145 | May 2010 → Jun 2013 | attention deficit-hyperactivity disorder | Shire | Completed | No outcome recorded |
| Phase 3 | NCT00997984 | Nov 2009 → Oct 2010 | attention deficit-hyperactivity disorder | Shire | Completed | No outcome recorded |
| Phase 3 | NCT00734578 | Sep 2008 → Dec 2009 | attention deficit-hyperactivity disorder | Shire | Completed | No outcome recorded |
| Phase 3 | NCT00367835 | Dec 2006 → Jan 2008 | attention deficit-hyperactivity disorder | Shire | Completed | No outcome recorded |
| Phase 3 | NCT00150618 | Mar → Oct 2004 | attention deficit-hyperactivity disorder | Shire | Completed | No outcome recorded |
| Phase 3 | NCT00152009 | Jan → Aug 2003 | attention deficit-hyperactivity disorder | Shire | Completed | No outcome recorded |
| Phase 3 | NCT00004376 | Sep 1994 → Jun 2000 | Tourette syndrome | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Phase 420 trials | ||||||
| Phase 4 | NCT06580041 | Nov 2024 → Sep 2029 expected | major depressive disorder | University of California, San Francisco | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT04181736 | Sep 2022 → Jan 2024 | major depressive disorder | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT05657860 | Dec 2020 → Dec 2023 | Prader-Willi syndrome, intellectual disability, neurotic excoriation, obesity disorder +1 | Maimonides Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT04066088 | Dec 2019 → Aug 2020 | Prader-Willi syndrome | NYU Langone Health | Withdrawn | No outcome recorded |
| Phase 4 | NCT04085172 | Sep 2019 → Sep 2025 | attention deficit-hyperactivity disorder | Shire | Completed | No outcome recorded |
| Phase 4 | NCT03258476 | Mar → Dec 2019 | anxiety disorder | UConn Health | Withdrawn | No outcome recorded |
| Phase 4 | NCT02699125 | Jan 2015 → Jun 2016 | obstructive sleep apnea syndrome | University of California, San Diego | Completed | No outcome recorded |
| Phase 4 | NCT01985581 | Oct 2013 → Mar 2015 | attention deficit-hyperactivity disorder | JPM van Stralen Medicine Professional | Completed | No outcome recorded |
| Phase 4 | NCT01547000 | Apr 2012 → Dec 2016 | Tourette syndrome | Yale University | Completed | No outcome recorded |
| Phase 4 | NCT01238575 | Dec 2011 → Mar 2014 | pervasive developmental disorder | Yale University | Completed | No outcome recorded |
| Phase 4 | NCT02048241 | Jul 2011 → Nov 2014 | attention deficit-hyperactivity disorder, conduct disorder, intermittent explosive disorder, oppositional defiant disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT01709695 | Mar 2011 → Dec 2013 | attention deficit-hyperactivity disorder | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 4 | NCT01133847 | Nov 2010 → Jun 2015 | attention deficit-hyperactivity disorder, reading disorder | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT01177306 | Jul 2010 → Dec 2013 | attention deficit-hyperactivity disorder | Lori A. Schweickert, MD | Completed | No outcome recorded |
| Phase 4 | NCT01156051 | Jun 2010 → Feb 2012 | attention deficit-hyperactivity disorder, insomnia | Children's Specialized Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT01146002 | Jun 2010 → Feb 2013 | attention deficit-hyperactivity disorder | Neurology Group of Bergen County, P.A. | Completed | No outcome recorded |
| Phase 4 | NCT01069523 | Mar 2010 → Aug 2011 | attention deficit-hyperactivity disorder | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 4 | NCT00429273 | Jan 2007 → Jul 2011 | attention deficit-hyperactivity disorder | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 4 | NCT00469664 | Feb 2000 → Aug 2008 | schizoaffective disorder, schizophrenia | Research Foundation for Mental Hygiene, Inc. | Unknown | No outcome recorded |
| Phase 4 | NCT00353379 | Sep 1995 → May 1997 | schizotypal personality disorder | Icahn School of Medicine at Mount Sinai | Terminated | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT03333668 | Oct 2018 → Dec 2022 | attention deficit-hyperactivity disorder | King's College London | Unknown | No outcome recorded |
| — | NCT02882854 | Nov 2016 → Feb 2017 | — | Vanderbilt University Medical Center | Completed | No outcome recorded |
| — | NCT02259517 | Sep 2014 → Nov 2021 | attention deficit-hyperactivity disorder | New York State Psychiatric Institute | Terminated | No outcome recorded |
| — | NCT00935493 | Jun 2009 → Aug 2012 | — | Yale University | Completed | No outcome recorded |
| — | NCT00358969 | Jul 2006 → ? | borderline personality disorder | Icahn School of Medicine at Mount Sinai | Unknown | No outcome recorded |
| — | NCT00025779 | Oct 2001 → Nov 2003 | attention deficit-hyperactivity disorder, autism | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
Also used as a comparator or background therapy in 16 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00919867 Comparator | Jun → Jul 2009 | — | Shire | Completed | No outcome recorded |
| Phase 1 | NCT00585754 Comparator | Apr 2006 → Jun 2016 | alcohol dependence, cocaine dependence | Yale University | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06042257 Comparator | Dec 2024 → May 2025 | developmental delay, impaired speech, and behavioral abnormalities, neurodevelopmental disorder with hypotonia, impaired speech, and behavioral abnormalities | Rachel G. Greenberg, MD, MB, MHS | Terminated | No outcome recorded |
| Phase 2 | NCT01470469 Comparator | Jan 2012 → Jul 2013 | generalized anxiety disorder, separation anxiety disorder, social phobia | Shire | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT03116126 Comparator | Jan 2019 → Aug 2024 | Alzheimer disease | Imperial College London | Unknown | No outcome recorded |
| Phase 3 | NCT00389675 Comparator | May 2007 → Feb 2010 | hypertensive disorder | Gilead Sciences | Terminated | No outcome recorded |
| Phase 3 | NCT00389779 Comparator | Sep 2006 → Aug 2009 | hypertensive disorder | Gilead Sciences | Completed | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT07300956 Comparator | Feb 2026 → Feb 2030 expected | attention deficit-hyperactivity disorder | Children's Hospital Medical Center, Cincinnati | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05916339 Comparator | Oct 2023 → Jan 2027 expected | attention deficit-hyperactivity disorder, autism spectrum disorder | Daniel Coury | Recruiting | No outcome recorded |
| Phase 4 | NCT01681264 Comparator | Sep 2014 → Dec 2022 | chronic pain syndrome | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT02204410 Background | Jul 2014 → May 2016 | attention deficit-hyperactivity disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02141113 Comparator | Nov 2012 → Sep 2014 | attention deficit-hyperactivity disorder | Rochester Center for Behavioral Medicine | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT02788851 Comparator | Apr 2016 → Dec 2018 | attention deficit-hyperactivity disorder | McGill University Health Centre/Research Institute of the McGill University Health Centre | Unknown | No outcome recorded |
| — | NCT02192398 Comparator | Sep 2014 → Oct 2022 | chronic pain syndrome | Massachusetts General Hospital | Terminated | No outcome recorded |
| — | NCT01600885 Comparator | Aug 2008 → Dec 2014 | — | Yale University | Completed | No outcome recorded |
| — | NCT00684489 Comparator | Sep 2003 → Mar 2005 | essential hypertension | Medical University of South Carolina | Completed | No outcome recorded |
Press releases naming this drug 9 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-08-13 | Takeda | New Drug Application Submitted in Japan for INTUNIV® (guanfacine hydrochloride extended release) in Adults with ADHD takeda.com ↗ |
| 2017-09-20 | Takeda | Shire and Shionogi Announce Positive Topline Results for INTUNIV® (guanfacine hydrochloride prolonged release) Evaluated in Phase 3 Clinical Trial in Adults with ADHD takeda.com ↗ |
| 2017-03-30 | Takeda | INTUNIV® (guanfacine hydrochloride prolonged release), a non-stimulant for the treatment of ADHD, receives approval in Japan takeda.com ↗ |
| 2015-09-21 | Takeda | Shire Receives European Approval for INTUNIV® ▼ (guanfacine hydrochloride prolonged release tablets) as a Non-stimulant ADHD Treatment for Children and Adolescents takeda.com ↗ |
| 2015-07-23 | Takeda | Shire receives CHMP Positive Opinion in Europe for INTUNIV®▼ (guanfacine hydrochloride extended release) as a non-stimulant ADHD treatment for children and adolescents takeda.com ↗ |
| 2015-06-02 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Enhances ADHD Product Line with Generic INTUNIV® in the United States tevapharm.com ↗ |
| 2014-03-27 | Takeda | Shire Submits INTUNIV® (Guanfacine Extended Release) Marketing Authorisation Application To EMA takeda.com ↗ |
| 2013-05-31 | Takeda | Shire Settles Patent Infringement Lawsuit Against Teva Concerning INTUNIV® takeda.com ↗ |
| 2013-04-25 | Takeda | Shire Settles All Pending Litigation With Actavis And Watson Concerning INTUNIV® takeda.com ↗ |
Evidence & citations 30 cited values
Every value below carries the sentence it was read from. 101 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | guanfacine | “Secondary outcomes include time to ejaculation by dose and orgasm quality scores using the Derogatis questionnaire and other questions as well as serum silodosin and guanfacine...” NCT07393334 ↗69“CAU plan modified to include a trial of methylphenidate (or, if contraindicated: guanfacine).” NCT06580041 ↗ “methyldopa, reserpine, guanfacine, hydralazine, minoxidil” NCT00684489 ↗ “SPD503 (Guanfacine Extended Release)-AM Optimized 1-4mg” NCT00734578 ↗ “Catapres, Clonidine, Guanfacine, Intuniv, Kapvay, Tenex” NCT05916339 ↗ “SPD503 (Guanfacine hydrochloride) (2 mg)” NCT00152009 ↗ “Guanfacine Extended Release (6mg/day ER)” NCT04198116 ↗ |
| Known as | Akfen | ChEMBL registry synonym — accepted as the source's own label CHEMBL862 ↗ |
| Known as | BS 100-141 | ChEMBL registry synonym — accepted as the source's own label CHEMBL862 ↗ |
| Known as | Estulic | ChEMBL registry synonym — accepted as the source's own label CHEMBL862 ↗ |
| Known as | Extended-release Guanfacine HCl | “The primary objective of this study is to evaluate the long-term maintenance of efficacy of Extended-Release Guanfacine HCl in children and adolescents (6-17 years) with...” NCT01081145 ↗1“Extended-release Guanfacine HCl (Intuniv, SPD503)” NCT01500694 ↗ |
| Known as | Extended-release guanfacine hydrochloride | “Extended-release guanfacine hydrochloride (GXR), a selective α2A-adrenergic agonist, is a nonstimulant medication for attention-deficit/hyperactivity disorder (ADHD).” PMID 26871297 ↗ Feb 20161“extended-release guanfacine hydrochloride (SPD503)” NCT00997984 ↗ |
| Known as | GFC | “This study aims to test the preliminary efficacy of 3.0 mg of guanfacine (GFC) daily versus placebo in cocaine and/or alcohol dependent individuals.” NCT00585754 ↗ |
| Known as | GIR | “The primary purpose of this study is to determine efficacy of guanfacine immediate release (GIR) for the treatment of hyperactivity/impulsivity and inattention in children 6-12...” NCT06042257 ↗ |
| Known as | GUA | “Guanfacine (GUA) medication brand names include: Intuniv, Tenex, guanfacine hydrochloride- extended release, guanfacine hydrochloride- immediate release” NCT07300956 ↗ |
| Known as | Guafacine hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL862 ↗ |
| Known as | GUAN | “Participants were randomized to 1 of 3 blinded conditions: guanfacine (GUAN), d-methylphenidate (DMPH), or the combination (COMB).” PMID 27453081 ↗ May 2016 |
| Known as | GUAN-IR | “This study examines cardiovascular (CV) effects of guanfacine immediate-release (GUAN-IR), dexmethylphenidate extended-release (DMPH), and their combination (COMB) during acute...” PMID 27483130 ↗ Aug 2016 |
| Known as | Guanfacina | ChEMBL registry synonym — accepted as the source's own label CHEMBL862 ↗ |
| Known as | guanfacine extended release | “OBJECTIVE: This is a feasibility study evaluating the safety, tolerability, and potential anxiolytic efficacy of the α2 agonist guanfacine extended-release (GXR) in children...” PMID 28165762 ↗ Feb 20179“Two studies have examined the adjunctive use of guanfacine extended release (GXR, Intuniv®; Shire Development LLC, Wayne, PA, USA) with psychostimulants in children and...” PMID 23615868 ↗ Jun 2013 “Data are reported from SPD503-318, a phase 3, open-label, safety study of guanfacine extended release (GXR) in European children and adolescents with...” PMID 29442229 ↗ Feb 2018 “Guanfacine extended-release (GXR), a selective α2A-adrenergic agonist, is a non-stimulant treatment for attention-deficit/hyperactivity disorder (ADHD).” PMID 25453486 ↗ Oct 2014 “This phase 3 trial evaluated the safety and efficacy of guanfacine extended release (GXR) in adolescents with ADHD.” PMID 26506582 ↗ Sep 2015 “study of guanfacine extended release (GXR) in children with ADHD” PMID 26547425 ↗ Nov 2015 “Guanfacine Extended Release (0.05mg/kg) tablet” NCT03333668 ↗ “Guanfacine extended release (GXR)” NCT04066088 ↗ “guanfacine extended release (GXR)” PMID 19877974 ↗ Oct 2009 |
| Known as | Guanfacine HCl | “We examine the effects of the alpha2 adrenergic agonist, guanfacine HCl, on responses to stress and drug cue in a group of cocaine-dependent men and women who also abuse...” PMID 24395021 ↗ Jan 2014 |
| Known as | Guanfacine hydrochloride | “A study to evaluate the long term maintenance of efficacy of using Guanfacine Hydrochloride (SPD-503) for the treatment of ADHD in Children aged 6-17 years in Europe,...” NCT03662763 ↗7“SPD503 (guanfacine hydrochloride) extended-release 4 mg orally administered tablets” NCT00901576 ↗ “SPD503 (extended-release Guanfacine hydrochloride)” NCT01470469 ↗ “SPD503 (Guanfacine hydrochloride) (2 mg)” NCT00152009 ↗ “SPD503 (Guanfacine hydrochloride)” NCT00367835 ↗ “SPD503 (Guanfacine hydrochloride)” NCT00151996 ↗ |
| Known as | Guanfacine Hydrochloride Immediate Release | “Guanfacine (GUA) medication brand names include: Intuniv, Tenex, guanfacine hydrochloride- extended release, guanfacine hydrochloride- immediate release” NCT07300956 ↗1“Drug: Guanfacine Hydrochloride Immediate Release” NCT06042257 ↗ |
| Known as | guanfacine hydrochloride- extended release | “Guanfacine (GUA) medication brand names include: Intuniv, Tenex, guanfacine hydrochloride- extended release, guanfacine hydrochloride- immediate release” NCT07300956 ↗ |
| Known as | Guanfacine immediate release | “The primary purpose of this study is to determine efficacy of guanfacine immediate release (GIR) for the treatment of hyperactivity/impulsivity and inattention in children 6-12...” NCT06042257 ↗1“Guanfacine immediate release, sold under the brand name Tenex among others, is a medication used to treat high blood pressure and off-label to treat attention deficit...” NCT04181736 ↗ |
| Known as | guanfacine-er | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05273567 ↗ |
| Known as | GXR | “OBJECTIVE: This is a feasibility study evaluating the safety, tolerability, and potential anxiolytic efficacy of the α2 agonist guanfacine extended-release (GXR) in children...” PMID 28165762 ↗ Feb 201715“The primary objective of the NorAD trial is to evaluate the change in cognition with 12 weeks of treatment of extended-release guanfacine (GXR) against a placebo as a...” PMID 35915506 ↗ Aug 2022 “Two studies have examined the adjunctive use of guanfacine extended release (GXR, Intuniv®; Shire Development LLC, Wayne, PA, USA) with psychostimulants in children and...” PMID 23615868 ↗ Jun 2013 “This will be a single-arm study in which the language-based academic skills of children diagnosed with ADHD will be assessed prior to, and then during treatment with...” NCT01146002 ↗ “Data are reported from SPD503-318, a phase 3, open-label, safety study of guanfacine extended release (GXR) in European children and adolescents with...” PMID 29442229 ↗ Feb 2018 “Extended-release guanfacine hydrochloride (GXR), a selective α2A-adrenergic agonist, is a nonstimulant medication for attention-deficit/hyperactivity disorder (ADHD).” PMID 26871297 ↗ Feb 2016 “Guanfacine Extended Release (GXR), the investigational drug in this study would be the first study to evaluate the drug in patients with Prader Willi Syndrome.” NCT05657860 ↗ “Guanfacine extended-release (GXR), a selective α2A-adrenergic agonist, is a non-stimulant treatment for attention-deficit/hyperactivity disorder (ADHD).” PMID 25453486 ↗ Oct 2014 “This phase 3 trial evaluated the safety and efficacy of guanfacine extended release (GXR) in adolescents with ADHD.” PMID 26506582 ↗ Sep 2015 “treatment with guanfacine extended release (GXR) in subjects with attention-deficit/hyperactivity disorder (ADHD)” PMID 21476931 ↗ Apr 2011 “Short-term, controlled studies of extended-release guanfacine (GXR), a selective alpha(2A)-adrenoreceptor agonist” PMID 19519256 ↗ Jun 2009 “Subjects were administered single oral doses of GXR (Intuniv(®); Shire Development LLC, Wayne, PA, USA) 4 mg” PMID 23519656 ↗ Mar 2013 “study of guanfacine extended release (GXR) in children with ADHD” PMID 26547425 ↗ Nov 2015 “guanfacine extended release (GXR; ≤4 mg/d)” PMID 22176941 ↗ Nov 2011 “Guanfacine extended release (GXR)” NCT04066088 ↗ “guanfacine extended release (GXR)” PMID 19877974 ↗ Oct 2009 |
| Known as | Intuniv | “Two studies have examined the adjunctive use of guanfacine extended release (GXR, Intuniv®; Shire Development LLC, Wayne, PA, USA) with psychostimulants in children and...” PMID 23615868 ↗ Jun 20136“This study is investigating the effect of sustained-release guanfacine (Intuniv) on language-based learning skills in children age 6-12 who are diagnosed with attention deficit...” NCT01146002 ↗ “Guanfacine (GUA) medication brand names include: Intuniv, Tenex, guanfacine hydrochloride- extended release, guanfacine hydrochloride- immediate release” NCT07300956 ↗ “guanfacine extended release (XR, Intuniv; Shire Development Inc., Wayne, PA, USA)” PMID 20806988 ↗ Sep 2010 “If Kapvay is ineffective or not tolerated, participants will progress to Intuniv.” NCT04737512 ↗ “Intuniv” NCT00901576 ↗ |
| Known as | Intuniv (TM) | “Intuniv (TM), guanfacine HCl, SPD503” NCT01156051 ↗ |
| Known as | NSC-759121 | ChEMBL registry synonym — accepted as the source's own label CHEMBL862 ↗ |
| Known as | SPD503 | “A study to evaluate the long term maintenance of efficacy of using Guanfacine Hydrochloride (SPD-503) for the treatment of ADHD in Children aged 6-17 years in Europe,...” NCT03662763 ↗10“SPD503 (Guanfacine Extended Release)-AM Optimized 1-4mg” NCT00734578 ↗ “extended-release guanfacine hydrochloride (SPD503)” NCT00997984 ↗ “Intuniv (TM), guanfacine HCl, SPD503” NCT01156051 ↗ “SPD503 (Guanfacine hydrochloride)” NCT00367835 ↗ “SPD503 (Guanfacine hydrochloride)” NCT00151996 ↗ “SPD503 (Guanfacine HCl)” NCT00150592 ↗ |
| Known as | Tenex | “Guanfacine immediate release, sold under the brand name Tenex among others, is a medication used to treat high blood pressure and off-label to treat attention deficit...” NCT04181736 ↗5“Children and adolescents who do not show a positive response to methylphenidate will be invited to participate in a pilot study of the non-stimulant medication guanfacine (Tenex).” NCT00025779 ↗ “Guanfacine (GUA) medication brand names include: Intuniv, Tenex, guanfacine hydrochloride- extended release, guanfacine hydrochloride- immediate release” NCT07300956 ↗ “guanfacine (Tenex)” NCT00358969 ↗ “Guanfacine/Tenex” NCT00469664 ↗ “Tenex” NCT02204410 ↗ |
| Action | Activate | “a selective alpha(2A)-adrenoceptor agonist” PMID 19106767 ↗ Feb 2009 |
| Modality | Small molecule | — CHEMBL862 ↗ |
| Route | Oral | “oral guanfacine” NCT00004376 ↗ |
| Target | ADRA2B | “single-nucleotide variants in the alpha-2 adrenergic receptor (ADRA2) subtype B, a G protein-coupled receptor expressed on peripheral and central presynaptic terminals” PMID 40326696 ↗ Oct 2025 |